论著

2017年至2021年上海嘉定区某医院多重耐药菌分析

展开
  • 上海交通大学医学院附属瑞金医院 a.检验科, b.院感科, 上海 201801

网络出版日期: 2022-02-25

基金资助

上海交通大学医学院附属瑞金医院院基金项目(2018ZY06)

Clinical isolates of multi drug resistant bacteria in a hospital from 2017 to 2021 in Jiading District of Shanghai

Expand
  • a. Department of Laboratory Medicine, b. Department of Hospital Infection, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai 201801, China

Online published: 2022-02-25

摘要

目的: 分析本地区近5年临床多重耐药菌的检出率和变化趋势以及碳青霉烯类耐药革兰阴性杆菌的耐药特征,为院内感染防控和抗菌药物经验治疗提供实验室依据。目的: 回顾性分析2017年1月至2021年12月住院患者临床标本分离的7种多重耐药菌的检出率,包括甲氧西林耐药金黄色葡萄球菌(methicillin resistant Staphylococcus aureus, MRSA)、万古霉素耐药肠球菌属细菌(vancomycin resistant Enterococcus, VRE)、产超广谱β-内酰胺酶大肠埃希菌(extended spectrum β-lactamases producing Escherichia coli, ESBL-eco)、产超广谱β-内酰胺酶肺炎克雷伯菌(extended spectrum β-lactamases producing Klebsiella pneumoniae, ESBL-kpn)、碳青霉烯类耐药肠杆菌目细菌(carbapenem resistant Enterobacteriaceae, CRE)、碳青霉烯类耐药鲍曼不动杆菌(carbapenem resistant Acinetobacter baumannii, CR-AB)和碳青霉烯类耐药铜绿假单胞菌(carbapenem resistant Pseudomonas aeruginosa, CR-PA),并分析碳青霉烯类耐药革兰阴性杆菌对常用抗菌药物的耐药率和CRE菌株的产碳青霉烯酶情况。结果: 本研究未检出VRE,除ESBL-eco外,其余5种多重耐药菌检出率在5年间呈上升趋势,MRSA、ESBL-kpn、CRE、CR-AB和CR-PA检出率分别波动在37.0%~53.6%、19.3%~34.3%、2.5%~10.6%、34.1%~63.4%和11.3%~22.8%;全院的CRE、CR-AB和CR-PA分离株中分别有65.4%、72.0%和59.3%分离自ICU。CRE和CR-AB对喹诺酮类、头孢类和β内酰胺酶抑制剂复合制剂等临床常用抗菌药物耐药率达90.0%;272株CRE中,肺炎克雷伯菌221株,占81.3%,对其中90株CRE菌株进行碳青霉烯酶检测,检出产KPC、NDM和IMP3种碳青霉烯酶,其中KPC酶构成比为90.0%。结论: 本研究6种多重耐药菌的检出率大多低于同期上海市和全国三级医院平均水平,但MRSA、ESBL-kpn、CRE、CR-AB和CR-PA呈上升趋势,应引起重视,尤其应关注ICU病区碳青霉烯类耐药革兰阴性杆菌耐药株。本研究检出CRE产3种碳青霉烯酶,其中90.0%为KPC酶。

本文引用格式

李丽, 朱咏臻, 周敏, 钱嘉, 方丽莉 . 2017年至2021年上海嘉定区某医院多重耐药菌分析[J]. 诊断学理论与实践, 2022 , 21(01) : 62 -67 . DOI: 10.16150/j.1671-2870.2022.01.012

Abstract

Objective: To analyze detection rate and changing trend of clinical multi-drug resistant bacteria(MDRB) in recent 5 years, and explore drug resistance characteristics of carbapenem resistant gram-negative bacteria, so as to provide reference for nosocomial infection prevention and control and empirical treatment of antibiotics in clinical practice. Methods: Seven kinds of MDRB isolated from clinical specimens of hospitalized patients during January 2017 to December 2021 were retrospectively analyzed, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), extended spectrum β-lactamases producing Escherichia coli (ESBL-eco), extended spectrum β-lactamases producing Klebsiella pneumoniae (ESBL-kpn), carbapenem resistant Enterobacteriaceae (CRE), carbapenem resistant Acinetobacter baumannii (CR-AB) and carbapenem resistant Pseudomonas aeruginosa (CR-PA). The rate of carbapenem resistant gram-negative bacilli to common antibiotics and the carbapenemase production of CRE strain were analyzed with SPSS 20.0. Results: VRE was not detected in this study. Except ESBL-eco, the isolated rates of the other five MDRB increased in the past five years. The detection rates of MRSA, ESBL-kpn, CRE, CR-AB and CR-PA fluctuated between 37.0%-53.6%, 19.3%-34.3%, 2.5%-10.6%, 34.1%-63.4% and 11.3%-22.8%, respectively. It revealed that 65.4% CRE, 72.0% CR-AB, and 59.3% CR-PA isolates were isolated from ICU. The resistant rates of CRE and CR-AB to quinolones, cephalosporins and β-Lactamase inhibitor complex were 90.0%. Among 272 CRE strains, 221 strains were Klebsiella pneumoniae, accounting for 81.3%. The carbapenemase was detected in 90 strains of CRE, in which three kinds of carbapenemases (KPC, NDM and IMP) were detected and the constituent ratio of KPC enzyme was 90.0%. Conclusions: The isolated rates of six MDRB in this study are much lower than the average level in Shanghai and national tertiary hospitals in the same period, but the isolated rates of MRSA, ESBL-kpn, CRE, CR-AB and CR-PA show an upward trend, which should be paid attention to, especially the carbapenem resistant gram-negative bacteria in ICU. In this study, 90 strains of CRE tested produced three kinds of carbapenem enzymes, in which KPC enzymes showed a high proportion.

参考文献

[1] Correa L, Martino MD, Siqueira I, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection[J]. BMC Infect Dis, 2013, 13:80.
[2] 黄勋, 邓子德, 倪语星, 等. 多重耐药菌医院感染预防与控制中国专家共识[J]. 中国感染控制杂志, 2015, 14(1):1-9.
[2] Huang X, Deng Z D, Ni Y X, et al. Consensus of Chinese experts on the prevention and control of nosocomial infection with multidrug resistant bacteria[J]. Chin J Infect Contr, 2015, 14(1):1-9.
[3] 李春辉. MDR、XDR、PDR多重耐药菌暂行标准定义—国际专家建议[J]. 中国感染控制杂志, 2014, 13(1):62-64.
[3] Li C H. Interim standard definition of MDR, XDR and PDR multidrug resistant bacteria-international expert recommendations[J]. Chin J Infect Contr, 2014, 13(1):62-64.
[4] 中国人民共和国卫生部. 多重耐药菌医院感染预防与控制技术指南(试行)[J]. 药学不良反应杂志, 2011, 13(2):108-109.
[4] Ministry of Health,People′s Republic of China Technical guidelines for the prevention and control of nosocomial infection by multidrug resistant bacteria(Trial)[J]. J Adverse Drug React, 2011, 13(2):108-109.
[5] 全国细菌耐药监测网. 全国细菌耐药监测网2014-2019年不同等级医院细菌耐药监测报告[J]. 中国感染控制杂志, 2021, 20(2):95-111.
[5] National bacterial resistance monitoring network. National bacterial drug resistance monitoring network 2014-2019 bacterial drug resistance monitoring report of different levels of hospitals[J]. Chin.J Infect Contr, 2021, 20(2):95-111.
[6] 吴湜, 胡付品, 蒋晓飞, 等. 2019年上海市三级医院细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21(1):1-10.
[6] Wu S, Hu F P, Jiang X F, et al. Surveillance of bacterial drug resistance in Shanghai tertiary hospitals in 2019[J]. Chin J Infect Chemother, 2021, 21(1):1-10.
[7] Strich JR, Palmore TN. Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit[J]. Infect Dis Clin North Am, 2017, 31(3):535-550.
[8] Tian L, Chen Z, Sun Z, et al. Antibiotic resistance profile of Enterobacter in hospitals across China: data from CHINET Antimicrobial Resistance Surveillance Program from 2005 through 2014[J]. Chin J Infect Chemother, 2016, 16:275e83.
[9] Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection[J]. Infect Control Hosp Epidemiol, 2010, 31(6):620-626.
[10] Boyle DP, Zembower TR. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond[J]. Urol Clin North Am, 2015, 42(4):493-505.
[11] Satlin MJ, Cohen N, Ma KC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies[J]. J Infect, 2016, 73(4):336-345.
[12] Iovleva A, Doi Y. Carbapenem-Resistant Enterobacte-riaceae[J]. Clin Lab Med, 2017, 37(2):303-315.
[13] Yin D, Dong D, Li K, et al. Clonal Dissemination of OXA-232 Carbapenemase-Producing Klebsiella pneumoniae in Neonates[J]. Antimicrob Agents Chemother, 2017, 61(8):e00385-e00317.
[14] Zhang W, Guo Y, Yang Y, et al. Study of In Vitro Syne-rgistic Bactericidal Activity of Dual β-Lactam Antibiotics Against KPC-2-Producing Klebsiella pneumoniae[J]. Microb Drug Resist, 2020, 26(3):204-210.
文章导航

/